Oncology

Phase I-III oncology expertise

We know that oncology drug development requires flexibility, determination and engaged study sites with close management. Trained in their therapeutic area and the specifics of your study protocol, our CRAs are regionally based, for a flexible, cost-effective and fully integrated approach.

Our experience in conducting Phase I/II adaptive oncology clinical trials, through to Phase III rescue studies has given us a deep understanding of managing complex hospital-based studies, supported by a world-leading oncology advisory board.

Your oncology study: from conception to delivery

Alain Thibault, Chairman of the Oncology Advisory Board

With 24 years of experience in oncology study delivery, our expertise enables us to successfully combine your business needs with those of the patients. Discover how.

Case Study

Case Study

Phase III rescue study, in patients with locally recurrent or metastatic breast cancer.

Read here

Case Study

Case Study

First in patient study, in patients with relapsed/refractory Non-Hodgkin’s Lymphoma and relapsed/refractory CLL.

Read here

Oncology

Oncology webinar

If you missed our live Precision Oncology: An Era that Calls for a New Model for Conducting Clinical Trials webinar discussion, you can view on demand now. What have we learned in the past five years, how do we design oncology trials in light of this new information, and how can we improve performance of oncology trials?

Watch now

Drug types

We have managed clinical trials with all products types including, vaccines, new chemical entities (NCEs), antisense therapy, small molecules, peptides, antibodies, genetically modified organisms (GMOs) and biologics, and gene therapy.

Let’s collaborate

If you think we could be right for you, get in touch.

Submit an RFI/RFP